On November 15, Pell Ann Wardrop, MD, walked into a testing center, where she sat down at a computer and took an exam.

On November 15, Pell Ann Wardrop, MD, walked into a testing center, where she sat down at a computer and took an exam.
During her presentation at the 2007 Combined Otolaryngology Spring Meeting in San Diego, Dana M. Hartl, MD, PhD, from the Department of Otolaryngology Head and Neck Surgery at the Institut Gustave Roussy in France, described her findings from a retrospective, bi-institutional study designed to review the results of a large series of patients with early glottic squamous cell carcinoma treated with curative intent by transoral laser resection.
Affecting more than 30 million Americans, chronic rhinosinusitis (CRS) has been a frustrating disease with no long-lasting results from traditional steroidal and antibiotic treatment, or from surgery. With both clinicians and patients desperate for a solution, it is not surprising that hope-and controversy-has arisen over a potential new therapy.
We all age, as our bodies unfailingly tell us. Muscles weaken, joints stiffen, hair thins, skin sags-the external signs are evident, albeit somewhat delayed and distorted in the increasing penchant toward masking time through cosmetics.
Experts agree that continuous positive airway pressure (CPAP) is the gold standard for management of obstructive sleep apnea.
If primary care physicians are to be believed, home is where the patient is-the Patient-Centered Medical Home (PC-MH), that is.
Non-acidic reflux is a major cause of laryngeal inflammation, and patients with this disorder present with a constellation of symptoms that differ from classic gastroesophageal reflux (GERD).
Physicians can successfully perform ultrasound-guided (US) fine-needle aspiration biopsy (FNAB) of thyroid nodules in the office instead of referring patients to a hospital-based radiologist for the procedure, according to new data presented at the annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery.
The targeted therapies erlotinib and cetuximab, in combination with standard chemotherapy regimens, are well tolerated and have very encouraging activity in recurrent/metastatic head and neck squamous cell carcinoma, according to two presentations at the American Society of Clinical Oncology (ASCO) 2007 Annual Meeting in Chicago.